Company: RVRC
Filing Date: 2025-08-13
Form Type: S-1/A
Source: 0001213900-25-075747
Chunk: 21

Company: Revium Rx.
Filing Date: 2025-08-13
Form: S-1/A
Chunk 21
---
The exclusive license granted to LipoVation
by Yissum under the Yissum License Agreements imposes various development, commercialization, funding, royalty, diligence, sublicensing,
insurance and other obligations on us. Our obligations under the Yissum License Agreements include, without limitation:

| ● | royalty payments; |

| ● | annual maintenance fees; |

<div align='center'>9</div>

| ● | providing progress reports; |

| ● | milestone payments |

| ● | maintaining insurance coverage; |

| ● | paying fees related to prosecution, maintenance and 
 enforcement of patent rights; and                   |

| ● | undertaking diligent efforts to develop and to introduce                
 therapeutic products into the commercial market as soon as practicable. |

These obligations subject us to the risk that
we may lose such license if we breach any of our material obligations described above and fail to remedy such material breach within
90 days (provided that such breach is curable within 90 days), or if we become bankrupt or insolvent, or if our business is placed in
the hands of a receiver, assignee or trustee, because Yissum has the right to terminate this license pursuant to the terms of the Yissum
License Agreements. This could result in inability of the Company to develop, manufacture and sell products that are covered by the licensed
technology pursuant to the Yissum License Agreements (the “Licensed Technology”) and could also result in competitors gaining
access to Licensed Technology.

The Israeli Contract Law (Remedies for Breach
of Contract) 1970, defines the term “material breach” as a breach, with regards to which, it may be assumed that a reasonable
person would not have entered into the specific agreement had that person foreseen the breach and the outcome thereof, or a breach which
is specifically defined as material in the agreement. Acts that may constitute a material breach of the license agreement by us may include,
for example: the granting of sublicenses not in compliance with the provisions of the license agreement, a breach of our obligations
to pay required license payments or royalties and provide the necessary reports with respect thereto, a breach of our obligations not
to disclose or misuse certain confidential information of Yissum, and a breach of our obligations to develop and commercialize the Licensed
Technology (including our obligation to fund certain research and development activities) and to conduct patent prosecution and maintenance.

Our Chief Financial Officer may face competing demands on his time and attention.

Our Chief Financial
Off